Indivior And Virginia Tech To Collaborate On Recover Study Extension
Wednesday, December 11, 2019
Indivior has announced a new research collaboration with Virginia Tech extending the RECOVER (Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery) Study ™. RECOVER is a multisite, non-interventional cohort study examining long-term recovery in individuals with moderate to severe opioid use disorder who received at least one dose of study treatment during the SUBLOCADE Phase 3 clinical trials. The study design and participant characteristics of the RECOVER study can be found in Contemporary Clinical Trials. This study will be led by a team of researchers at the Fralin Biomedical Research Institute at Virginia Tech Carilion.
"The Virginia Tech-Indivior study is a powerful example of how academia and industry can collaborate to address a major health care problem that is causing tremendous hardship throughout the United States, particularly here in Virginia," said Michael Friedlander, Vice President for Health Sciences and Technology at Virginia Tech and the Executive Director of the Fralin Biomedical Research Institute. "Together we are determined to find scientifically sound solutions to the opioid crisis."
The study will be carried out by a team of researchers led by Warren Bickel, a Virginia Tech addiction researcher and professor at the Fralin Biomedical Research Institute.
Researchers hope the extended study may also provide further information to health care systems and policy-makers on how successful treatment and long-term recovery can reduce the economic burden of opioid use disorder. The scope and duration of these assessments may also lead to important new insights into theoretical models of recovery and allow researchers, clinicians, and patients to more accurately characterize the process of recovery, identify factors that promote or hinder success, and develop new and personalized treatment strategies.
"We believe that this Virginia Tech-Indivior study, which will actively engage patients in their real-world environment, will contribute to a better understanding of how patients are able to pursue the life changes they aspire to achieve, which is what true recovery is all about" said Dr. Christian Heidbreder, Chief Scientific Officer, Indivior, Inc.